Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7655205 | 1.00 | TYR (0.48) | TYRALDH1A1SMN1; SMN2LGALS8SLC5A2 | |
| SCHEMBL7655341 | 0.92 | TYR (0.55) | TYRSLC5A2POLB | |
| SCHEMBL7655345 | 0.92 | TYR (0.55) | TYRSLC5A2POLB | |
| SCHEMBL7662298 | 0.92 | TYR (0.55) | TYRALDH1A1SMN1; SMN2SLC5A2POLB | |
| SCHEMBL7662306 | 0.92 | TYR (0.55) | TYRALDH1A1SMN1; SMN2SLC5A2POLB | |
| SCHEMBL7659560 | 0.89 | TYR (0.44) | TYRLGALS8 | |
| SCHEMBL7697430 | 0.89 | TYR (0.55) | TYRLGALS8POLB | |
| SCHEMBL7654577 | 0.89 | TYR (0.51) | TYRALDH1A1SMN1; SMN2LGALS8 | |
| SCHEMBL7654565 | 0.89 | TYR (0.51) | TYRALDH1A1SMN1; SMN2LGALS8 | |
| SCHEMBL7657467 | 0.89 | TYR (0.51) | TYRALDH1A1SMN1; SMN2LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492335-B1 | Glycoconjugates from modified camptothecin derivatives (20-O-linkage) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| EP-0934329-B1 | GLYCOCONJUGATES FROM MODIFIED CAMPTOTHECIN DERIVATES (20-O-LINKAGE) | BAYER AG (DE) | 2001-12-12 | — | — | EP | disclosed |
| EP-0939765-B1 | GLYCOCONJUGATES OF MODIFIED CAMPTOTHECIN DERIVATIVES (A- OR B-RING LINKAGE) | BAYER AG (DE) | 2001-12-05 | — | — | EP | disclosed |
| US-6271342-B1 | SERUM STABILITY; FOR TUMOR THERAPY | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | disclosed |
| US-6156754-A | Glycoconjugates of modified camptothecin derivatives (A-or B-ring linkage) | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-05 | — | — | US | disclosed |
| EP-0819135-B1 | SUGAR-MODIFIED CYTOSTATICS | BAYER AG (DE) | 1999-11-17 | — | — | EP | disclosed |